Norepinephrine-induced delayed cardioprotection against stunning is at the expense of a higher postischemic arrhythmia rate.
alpha(1)-adrenoceptor activation confers myocardial protection from ischemic injury. We tested whether norepinephrine mediates delayed cardioprotection against stunning and whether this alters postischemic arrhythmias. New Zealand White rabbits were assigned to three groups: Control-group (n=7): no drugs. Norepinephrine-group (n=7): 75 microg norepinephrine/kg bodyweight (bw). Norepinephrine/prazosin-group (n=7):75 microg norepinephrine and 15 microg prazosin/kg bw. After 24 h, hearts were excised, perfused with buffer and subjected to 20 min of ischemia followed by 120 min of reperfusion. (a) Developed pressures (dP) (P(syst)-P(diast)) at the end of reperfusion: C: 51.2+/-5.0%, NE: 71.7+/-5.1% (p<0.05 vs. C), NEP: 50.7+/-5.0%. (b) Ventricular extra beats (vebs) were detected throughout the experiments. C: 0.41+/-0.15 vebs/min, NE: 1.06+/-0.18 vebs/min (p<0.05 vs. C), NEP: 1.17+/-0.3 vebs/min. Norepinephrine confers delayed preconditioning against myocardial stunning via an alpha(1)-adrenoceptor mediated pathway. Norepinephrine-mediated preconditioning involves a beneficial effect towards stunning, but at the expense of a higher rate of postischemic ventricular arrhythmia.